Drugs / APZ2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02742844 | Aug 2016 → Jan 2019 | chronic ulcer of skin | RHEACELL GmbH & Co. KG | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APZ2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02742844 ↗ |
| Modality | Cell therapy | “ABCB5+ mesenchymal stem cells (MSCs)” NCT02742844 ↗ |
| Route | Topical | “will then be applied on the wound surface of CVU” NCT02742844 ↗ |